About AVT
Browse Articles
Customer Services

Case report

Efavirenz in an obese HIV-infected patient – a report and an in vitroin vivo extrapolation model indicate risk of underdosing

Mirjam de Roche, Marco Siccardi, Marcel Stoeckle, Françoise Livio, David Back, Manuel Battegay, Catia Marzolini

Corresponding author name: Catia Marzolini
Corresponding author e-mail: MarzoliniC@uhbs.ch

Citation: Antiviral Therapy 2012; 17:1381-1384
doi: 10.3851/IMP2107

Date accepted: 09 February 2012
Date published online: 24 April 2012


Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitroin vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.